Severe infection risk in patients treated with biologics for rheumatoid arthritis: a systematic review protocol.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
pubmed:
15
4
2021
medline:
3
11
2021
entrez:
14
4
2021
Statut:
ppublish
Résumé
The objective of this review is to estimate the population-based incidence and to determine the types of severe infection experienced by patients with rheumatoid arthritis who are taking biological agents. Since the late 1990s, a variety of biological and synthetic drugs have been developed to treat rheumatoid arthritis. In recent years, the incidence of severe infection in patients with rheumatoid arthritis in Western nations has been reported by observational studies; however, no systematic review has been conducted on this topic. The following criteria will be considered for inclusion: i) observational studies on patients with rheumatoid arthritis who are taking biological agents; ii) studies reporting the number of severe infections requiring hospitalization for treatment; and iii) studies with person-years of observational data. MEDLINE, CINAHL, Embase, and Web of Science will be searched to identify published studies. The reference lists of all studies that are selected for critical appraisal will be screened for additional studies. The search for unpublished studies will include MedNar and OpenGrey. Only studies published in English from 1999 to the present will be included. Screening of studies, assessment of methodological quality, and data extraction will be performed by two independent reviewers. If possible, studies will be pooled in statistical meta-analysis. PROSPERO CRD42020175137.
Identifiants
pubmed: 33851946
doi: 10.11124/JBIES-20-00372
pii: 02174543-900000000-99694
doi:
Substances chimiques
Biological Factors
0
Biological Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1992-1998Informations de copyright
Copyright © 2021 JBI.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Aggarwal D, Abraham S. Rheumatoid arthritis treatments: a historical perspective. JSM Arthritis 2016;1 (2):1011–1020.
Allaire S, Wolfe F, Niu J, Lavalley M. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum 2008;59 (4):474–480.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295 (19):2275–2285. 17.
Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020;79:760–770.
Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386:258–265.
Jani M, Barton A, Hyrich K. Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? Curr Opin Rheumatol 2019;31 (3):285–292.
Cabral VP, de Andrade CAF, Passos SRL, Martins MFM, Hökerberg YHM. Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies. Rev Bras Reumatol 2016;56 (6):543–550.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62 (9):2569–2581.
Sokolove J, Strand V. Rheumatoid arthritis classification criteria – it's finally time to move on!. Bull NYU Hosp Jt Dis 2010;68 (3):232–238.
Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2011;84 (11):1245–1252.
American College of Clinical Pharmacy, Burke RA, White ND. Murphy JE, Lee MW. Biologic disease-modifying anti-rheumatic drugs. PSAP 2014 Book 2 (Chronic illnesses): Pharmacotherapy self-assessment program 2014; 9–31.
Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc 2015;13 (3):147–153.
Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6 (7):e1000097.